Estimating the direct costs of bowel cancer services provided by the National Health Service in England
- 13 October 2010
- journal article
- assessments
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 26 (4) , 362-369
Abstract
Objectives:Bowel cancer is the second most common cancer in England and Wales, accounting for approximately 13,000 deaths per year. Economic evaluations and national guidance have been produced for individual treatments for bowel cancer. However, it has been suggested that Primary Care Trusts develop program budgeting or equivalent methodology demonstrating a whole system approach to investment and disinvestment. The objective of this study was to provide a baseline framework for considering a whole system approach to estimate the direct costs of bowel cancer services provided by the National Health Service (NHS) in England.Methods:A treatment pathway, developed in 2005, was used to construct a service pathway model to estimate the direct cost of bowel cancer services in England.Results:The service pathway model estimated the direct cost of bowel cancer services to the NHS to be in excess of £1 billion in 2005. Thirty-five percent of the cost is attributable to the screening and testing of patients with suspected bowel cancer, subsequently diagnosed as cancer-free.Conclusions:This study is believed to be the most comprehensive attempt to identify the direct cost of managing bowel cancer services in England. The approach adopted could be useful to assist local decision makers in identifying those aspects of the pathway that are most uncertain in terms of their cost-effectiveness and as a basis to explore the implications of re-allocated resources. Research recommendations include the need for detailed costs on surgical procedures, high-risk patients and the utilization of the methods used in this study across other cancers.Keywords
This publication has 19 references indexed in Scilit:
- The costs and benefits of bowel cancer service developments using discrete event simulationJournal of the Operational Research Society, 2009
- Use of expert knowledge in evaluating costs and benefits of alternative service provisions: A case studyInternational Journal of Technology Assessment in Health Care, 2008
- Projections of the costs associated with colorectal cancer care in the United States, 2000–2020Health Economics, 2007
- Uncertain Judgements: Eliciting Experts' Probabilities2006
- Routine short course pre-op radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trialJournal of Clinical Oncology, 2006
- Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Capecitabine as Adjuvant Treatment for Stage III Colon CancerNew England Journal of Medicine, 2005
- Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon CancerNew England Journal of Medicine, 2004
- A Comparison of Laparoscopically Assisted and Open Colectomy for Colon CancerNew England Journal of Medicine, 2004
- Cancer prevalence in the UK: results from the EUROPREVAL studyAnnals of Oncology, 2003